You are here

Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?

Scheduled Maintenance Notice: is scheduled to undergo maintenance on Monday, March 27th starting at 9am and ending at 3pm (PDT). The website will be inaccessible during the maintenance window. If you have any questions, please contact us at


Warning message

This webinar is restricted to registered participants or on-demand registrants. Click the following link to register: Register Here

Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?

You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?

Learning Objectives:

  1. Review the published evidence base supporting TMS maintenance treatments after a successful acute course for depression; 
  2. Identify the areas of gap in the evidence base and their implications; 
  3. Consider the rationale behind several different approaches to maintenance care with TMS.

Date of Release: April 9, 2021

Date of Expiration: April 8, 2023


Cost: Members: $25 | Non-members $50 | Student Members FREE

Member Access Instructions

Non-Member Access Instructions

SPEAKER: Linda Carpenter, MD

Linda L. Carpenter, MD is a Professor of Psychiatry in the Alpert Medical School of Brown University and Director of the Butler Hospital TMS Clinic and Neuromodulation Research Facility. She completed her undergraduate degree at the University of Michigan and medical school at the University of Pennsylvania. She did an internship in internal medicine, psychiatry residency, and research fellowship at Yale, then joined the faculty at Brown in 1997. She has continued her path since then as a physician-researcher investigating the neurobiology of, and new treatments for, major depression and other mood and anxiety disorders. Dr. Carpenter has also conducted a number of randomized clinical trials sponsored by industry and NIH, investigating investigational drugs and devices for treating depression, including esketamine, Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS). She was engaged in TMS research prior to the first FDA clearance in 2008, and has remained active as a TMS clinician and researcher since then. She is Deputy Director of the new NIGMS-funded COBRE Center for Neuromodulation at Butler Hospital, as well as Director of the Center’s Neuromodulation and Neuroimaging Core. In addition to her leadership roles within CTMSS,  Dr. Carpenter serves on the American Psychiatric Association (APA) Council on Research and she has published extensively on TMS and other neuromodulation treatments for depression.

Vertical Tabs

Vertical Tabs